November 23, 2010
SALIX PHARMACEUTICALS TO PRESENT AT PIPER JAFFRAY CONFERENCE
November 08, 2010
Salix Pharmaceuticals Reports 3Q2010 Results
November 04, 2010
Crofelemer ADVENT Trial Demonstrates Highly Statistically Significant Results in the Treatment of HIV-Associated Diarrhea
November 03, 2010
Salix Pharmaceuticals to Present at Credit Suisse Conference
October 30, 2010
Salix Pharmaceuticals Previews Data Slated For Presentation at 61st Annual Meeting Of The American Association For The Study Of Liver Diseases
October 27, 2010
Salix Pharmaceuticals Launches Corporate Twitter Account and Facebook Page
October 25, 2010
Salix Pharmaceuticals Announces 3Q2010 Financial Results Conference Call And Webcast
October 20, 2010
Salix Pharmaceuticals Acquires Lumacan™ From Photocure
October 18, 2010
XIFAXAN 550 Mg (Rifaximin) Demonstrates Acute And Sustained Relief Of Non-Constipation Irritable Bowel Syndrome Symptoms: Data Presented At The 2010 American College Of Gastroenterology (ACG) Annual Meeting
October 04, 2010
Salix Pharmaceuticals Announces Extension of XIFAXAN550 sNDA PDUFA Goal Date to March 7, 2011
September 29, 2010
Salix Pharmaceuticals to Present at Jefferies Conference
September 21, 2010
Salix Pharmaceuticals to Present at JMP Conference
September 09, 2010
Salix Pharmaceuticals to Present at Stifel Nicolaus Conference
August 31, 2010
Salix Pharmaceuticals Announces Settlement of Pending Litigation Regarding MOVIPREP®
August 09, 2010
Salix Pharmaceuticals Reports 2Q2010 Results
August 09, 2010
Salix Announces FDA Acceptance For Filing And Priority Review Designation For Xifaxan550 sNDA For The Treatment Of Non-Constipation Irritable Bowel Syndrome
August 05, 2010
Salix Pharmaceuticals to Present at Bank of America Merrill Lynch Conference
July 29, 2010
Salix Pharmaceuticals To Present at BMO Capital Markets Conference
July 26, 2010
Salix Pharmaceuticals Announces 2Q2010 Financial Results Conference Call And Webcast
June 16, 2010
Salix Pharmaceuticals To Present At NASDAQ Conference
June 08, 2010
Salix Pharmaceuticals Announces NDA Submission For Xifaxan550 For Treatment Of Non-Constipation Irritable Bowel Syndrome
June 01, 2010
Salix Pharmaceuticals To Present At Jefferies Conference
May 27, 2010
Salix Pharmaceuticals Announces Pricing Of Its $300 Million Public Offering Of Convertible Senior Notes Due 2015
May 27, 2010
Salix Pharmaceuticals Announces Proposed $200 Million Public Offering Of Convertible Senior Notes Due 2015
May 24, 2010
XIFAXAN® (Rifaximin) 550 mg Tablets Now Available In U.S. Pharmacies